Skip to main content
Journal cover image

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

Publication ,  Journal Article
Cornell, R; Hari, P; Tang, S; Biran, N; Callander, N; Chari, A; Chhabra, S; Fiala, MA; Gahvari, Z; Gandhi, U; Godby, K; Gupta, R; Jagosky, M ...
Published in: Am J Hematol
January 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

January 2021

Volume

96

Issue

1

Start / End Page

E5 / E8

Location

United States

Related Subject Headings

  • Triazoles
  • Survival Rate
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Hydrazines
  • Humans
  • Female
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., … Costa, L. (2021). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol, 96(1), E5–E8. https://doi.org/10.1002/ajh.26010
Cornell, Robert, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Ajai Chari, Saurabh Chhabra, et al. “Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.Am J Hematol 96, no. 1 (January 2021): E5–8. https://doi.org/10.1002/ajh.26010.
Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, et al. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 Jan;96(1):E5–8.
Cornell, Robert, et al. “Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.Am J Hematol, vol. 96, no. 1, Jan. 2021, pp. E5–8. Pubmed, doi:10.1002/ajh.26010.
Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 Jan;96(1):E5–E8.
Journal cover image

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

January 2021

Volume

96

Issue

1

Start / End Page

E5 / E8

Location

United States

Related Subject Headings

  • Triazoles
  • Survival Rate
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Hydrazines
  • Humans
  • Female
  • Disease-Free Survival